Article Details
Retrieved on: 2024-03-11 16:46:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Alumis Inc., a biopharmaceutical company, focusing on developing oral therapies targeting tyrosine kinase 2 for immune-mediated diseases like uveitis, within the broader field of immunology.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here